Patents by Inventor Masanori Okaniwa

Masanori Okaniwa has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTIBODY-DRUG CONJUGATES COMPRISING A CYCLIC DINUCLEOTIDE
    Publication number: 20240066047
    Abstract: The present disclosure provides a compound having a STING agonistic activity, which may be expected to be useful as an agent for the prophylaxis or treatment of STING-related diseases. The present disclosure relates to a compound represented by the formula (I): wherein each symbol is as defined in the description, or a salt thereof.
    Type: Application
    Filed: May 1, 2023
    Publication date: February 29, 2024
    Inventors: MASATO YOSHIKAWA, MORIHISA SAITOH, TAISUKE KATO, YAYOI NAKAYAMA, TOMOHIRO SEKI, YASUO NAKAGAWA, YUSUKE TOMINARI, MASAKI SETO, YUSUKE SASAKI, MASANORI OKANIWA, TSUNEO ODA, AKITO SHIBUYA, KOSUKE HIDAKA, ZENYU SHIOKAWA, SHUMPEI MURATA, ATSUTOSHI OKABE, YOSHIHISA NAKADA, MICHIYO MOCHIZUKI, BRIAN SCOTT FREEZE, TAISUKE TAWARAISHI, YASUFUMI WADA, PAUL D. GREENSPAN
  • mTORC1 INHIBITORS
    Publication number: 20240066134
    Abstract: Disclosed herein, inter alia, are compounds and methods of using the same for modulating the activity of mTORC1.
    Type: Application
    Filed: February 28, 2023
    Publication date: February 29, 2024
    Inventors: Kevan Shokat, Masanori Okaniwa
  • Antibody-drug conjugates comprising a cyclic dinucleotide
    Patent number: 11666594
    Abstract: The present disclosure provides a compound having a STING agonistic activity, which may be expected to be useful as an agent for the prophylaxis or treatment of STING-related diseases. The present disclosure relates to a compound represented by the formula (I): wherein each symbol is as defined in the description, or a salt thereof.
    Type: Grant
    Filed: October 7, 2020
    Date of Patent: June 6, 2023
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Masato Yoshikawa, Morihisa Saitoh, Taisuke Kato, Yayoi Nakayama, Tomohiro Seki, Yasuo Nakagawa, Yusuke Tominari, Masaki Seto, Yusuke Sasaki, Masanori Okaniwa, Tsuneo Oda, Akito Shibuya, Kosuke Hidaka, Zenyu Shiokawa, Shumpei Murata, Atsutoshi Okabe, Yoshihisa Nakada, Michiyo Mochizuki, Brian Scott Freeze, Taisuke Tawaraishi, Yasufumi Wada, Paul D. Greenspan
  • LIPID COMPOSITIONS FOR DELIVERY OF STING AGONIST COMPOUNDS AND USES THEREOF
    Publication number: 20230149560
    Abstract: The present disclosure provides lipid compositions comprising lipid particles (e.g., lipid nanodiscs), wherein the lipid particles (e.g., lipid nanodiscs) comprise a STING agonist amphiphile conjugate, a phospholipid and a PEG-lipid. The compositions are used in methods to induce or promote immune responses, such as immune responses useful for the treatment of cancer or infectious disease.
    Type: Application
    Filed: April 20, 2021
    Publication date: May 18, 2023
    Inventors: Darrell J. IRVINE, Eric DANE, Masanori OKANIWA
  • Sting modulator compounds, and methods of making and using
    Patent number: 11542293
    Abstract: The present disclosure provides STING modulators/agonists, and methods of synthesis and methods for using for the prophylaxis or treatment of cancer and other STING-related diseases. The present disclosure relates to a compound represented by the Formula (I): wherein each symbol is as defined in the description, or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: November 9, 2018
    Date of Patent: January 3, 2023
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Stepan Vyskocil, Jeffrey Ciavarri, Courtney Cullis, Dylan Bradley England, Alexandra E. Gould, Paul Greenspan, Yongbo Hu, Steven Langston, Gang Li, Hirotake Mizutani, Masanori Okaniwa
  • Mtorc1 inhibitors
    Patent number: 11452780
    Abstract: Disclosed herein, inter alia, are compounds and methods of using the same for modulating the activity of mTORC1.
    Type: Grant
    Filed: March 24, 2020
    Date of Patent: September 27, 2022
    Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Kevan Shokat, Masanori Okaniwa
  • STING MODULATOR COMPOUNDS, AND METHODS OF MAKING AND USING
    Publication number: 20210171565
    Abstract: The present disclosure provides STING modulators/agonists, and methods of synthesis and methods for using for the prophylaxis or treatment of cancer and other STING-related diseases. The present disclosure relates to a compound represented by the Formula (I): wherein each symbol is as defined in the description, or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: November 9, 2018
    Publication date: June 10, 2021
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Stepan VYSKOCIL, Jeffrey CIAVARRI, Courtney CULLIS, Dylan Bradley ENGLAND, Alexandra E. GOULD, Paul GREENSPAN, Yongbo HU, Steven LANGSTON, Gang LI, Hirotake MIZUTANI, Masanori OKANIWA
  • ANTIBODY-DRUG CONJUGATES COMPRISING A CYCLIC DINUCLEOTIDE
    Publication number: 20210106607
    Abstract: The present disclosure provides a compound having a STING agonistic activity, which may be expected to be useful as an agent for the prophylaxis or treatment of STING-related diseases. The present disclosure relates to a compound represented by the formula (I): wherein each symbol is as defined in the description, or a salt thereof.
    Type: Application
    Filed: October 7, 2020
    Publication date: April 15, 2021
    Inventors: MASATO YOSHIKAWA, Morihisa Saitoh, Taisuke Kato, Yayoi Nakayama, Tomohiro Seki, Yasuo Nakagawa, Yusuke Tominari, Masaki Seto, Yusuke Sasaki, Masanori Okaniwa, Tsuneo Oda, Akito Shibuya, Kosuke Hidaka, Zenyu Shiokawa, Shumpei Murata, Atsutoshi Okabe, Yoshihisa Nakada, Michiyo Mochizuki, Brian Scott Freeze, Taisuke Tawaraishi, Yasufumi Wada, Paul D. Greenspan
  • mTORC1 INHIBITORS
    Publication number: 20210052735
    Abstract: Disclosed herein, inter alia, are compounds and methods of using the same for modulating the activity of mTORC1.
    Type: Application
    Filed: March 24, 2020
    Publication date: February 25, 2021
    Inventors: Kevan Shokat, Masanori Okaniwa
  • Heterocyclic amide compound
    Patent number: 10800754
    Abstract: Provided is a heterocyclic amide compound that may have a PRS inhibitory action and is expected to be useful as a prophylactic or therapeutic agent for PRS associated diseases and the like including cancer. A compound represented by the following formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof.
    Type: Grant
    Filed: September 14, 2017
    Date of Patent: October 13, 2020
    Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Takaharu Hirayama, Yasuhiro Hirata, Yusuke Tominari, Naoki Iwamura, Yusuke Sasaki, Moriteru Asano, Terufumi Takagi, Masanori Okaniwa, Masato Yoshida, Shinichi Imamura
  • Heterocyclic amide compound
    Patent number: 10774083
    Abstract: Provided is a heterocyclic amide compound that may have a PRS inhibitory action and is expected to be useful as a prophylactic or therapeutic agent for PRS associated diseases and the like including cancer. A compound represented by the following formula (I): wherein a group represented by is a group represented by the following formula (II) or the following formula (III): and other symbols are as described in the DESCRIPTION, or a salt thereof.
    Type: Grant
    Filed: September 14, 2017
    Date of Patent: September 15, 2020
    Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Takaharu Hirayama, Yasuhiro Hirata, Yusuke Tominari, Naoki Iwamura, Yusuke Sasaki, Moriteru Asano, Terufumi Takagi, Masanori Okaniwa, Shinichi Imamura
  • mTORC1 inhibitors
    Patent number: 10646577
    Abstract: Disclosed herein, inter alia, are compounds and methods of using the same for modulating the activity of mTORC1.
    Type: Grant
    Filed: September 10, 2018
    Date of Patent: May 12, 2020
    Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Kevan Shokat, Masanori Okaniwa
  • HETEROCYCLIC AMIDE COMPOUND
    Publication number: 20190359587
    Abstract: Provided is a heterocyclic amide compound that may have a PRS inhibitory action and is expected to be useful as a prophylactic or therapeutic agent for PRS associated diseases and the like including cancer. A compound represented by the following formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof.
    Type: Application
    Filed: September 14, 2017
    Publication date: November 28, 2019
    Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Takaharu HIRAYAMA, Yasuhiro HIRATA, Yusuke TOMINARI, Naoki IWAMURA, Yusuke SASAKI, Moriteru ASANO, Terufumi TAKAGI, Masanori OKANIWA, Masato YOSHIDA, Shinichi IMAMURA
  • HETEROCYCLIC AMIDE COMPOUND
    Publication number: 20190241566
    Abstract: Provided is a heterocyclic amide compound that may have a PRS inhibitory action and is expected to be useful as a prophylactic or therapeutic agent for PRS associated diseases and the like including cancer. A compound represented by the following formula (I): wherein a group represented by is a group represented by the following formula (II) or the following formula (III): and other symbols are as described in the DESCRIPTION, or a salt thereof.
    Type: Application
    Filed: September 14, 2017
    Publication date: August 8, 2019
    Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Takaharu HIRAYAMA, Yasuhiro HIRATA, Yusuke TOMINARI, Naoki IWAMURA, Yusuke SASAKI, Moriteru ASANO, Terufumi TAKAGI, Masanori OKANIWA, Masato YOSHIDA, Takashi ICHIKAWA, Shinichi IMAMURA
  • CYCLIC DINUCLEOTIDE
    Publication number: 20190192549
    Abstract: The present disclosure provides a compound having a STING agonistic activity, which may be expected to be useful as an agent for the prophylaxis or treatment of STING-related diseases. The present disclosure relates to a compound represented by the formula (I): wherein each symbol is as defined in the description, or a salt thereof.
    Type: Application
    Filed: November 9, 2018
    Publication date: June 27, 2019
    Inventors: MASATO YOSHIKAWA, Morihisa Saitoh, Taisuke Kato, Yayoi Yoshitomi, Tomohiro Seki, Yasuo Nakagawa, Yusuke Tominari, Masaki Seto, Yusuke Sasaki, Masanori Okaniwa, Tsuneo Oda, Akito Shibuya, Kosuke Hidaka, Zenyu Shiokawa, Shumpei Murata, Atsutoshi Okabe, Yoshihisa Nakada, Michiyo Mochizuki, Brian Scott Freeze, Taisuke Tawaraishi, Yasufumi Wada, Paul D. Greenspan
  • mTORC1 INHIBITORS
    Publication number: 20190091340
    Abstract: Disclosed herein, inter alia, are compounds and methods of using the same for modulating the activity of mTORC1.
    Type: Application
    Filed: September 10, 2018
    Publication date: March 28, 2019
    Inventors: Kevan Shokat, Masanori Okaniwa
  • mTORC1 inhibitors
    Patent number: 10117945
    Abstract: Disclosed herein, inter alia, are compounds and methods of using the same for modulating the activity of mTORC1.
    Type: Grant
    Filed: March 10, 2017
    Date of Patent: November 6, 2018
    Assignee: The Regents of the University of California
    Inventors: Kevan Shokat, Masanori Okaniwa
  • Heterocyclic compound
    Patent number: 9957251
    Abstract: The present invention provides a heterocyclic compound having a CDK8 and/or CDK19 inhibitory effect. The present invention provides a compound represented by formula (I) (in the formula, the symbols are as defined in the description) or a salt thereof.
    Type: Grant
    Filed: April 16, 2015
    Date of Patent: May 1, 2018
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Takaharu Hirayama, Jun Fujimoto, Douglas Robert Cary, Masanori Okaniwa, Yasuhiro Hirata
  • mTORC1 INHIBITORS
    Publication number: 20170246305
    Abstract: Disclosed herein, inter alia, are compounds and methods of using the same for modulating the activity of mTORC1.
    Type: Application
    Filed: March 10, 2017
    Publication date: August 31, 2017
    Inventors: Kevan Shokat, Masanori Okaniwa
  • Fused heterocyclic compound
    Patent number: 9745325
    Abstract: The present invention provides a fused heterocyclic compound that has CDK 8 and/or CDK 19 inhibitory activity. The present invention provides a compound represented by formula (I) (wherein the symbols are as defined in the description) or a salt thereof.
    Type: Grant
    Filed: April 16, 2015
    Date of Patent: August 29, 2017
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Masanori Okaniwa, Hiroshi Banno, Takaharu Hirayama, Douglas Robert Cary, Koji Ono, Naoki Iwamura